Delivering safer and more effective conditioning for patients
Delivering safer and more effective conditioning for patients
Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.
JSP191 (formerly AMG191) is a first-in-class humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow. JSP191 binds to human CD117, a receptor for stem cell factor (SCF) that is expressed on the surface of hematopoietic stem and progenitor cells. The interaction of SCF and CD117 is required for stem cells to survive. JSP191 blocks SCF from binding to CD117 and disrupts critical survival signals, causing the stem cells to undergo cell death and creating an empty space in the bone marrow for donor or gene-corrected transplanted cells to engraft.
Preclinical studies have shown that JSP191 as a single agent suppresses human hematopoiesis and safely depletes hematopoietic stem cells, including in an animal model of MDS. To date, JSP191 has been evaluated in more than 80 healthy volunteers and patients. It is currently being evaluated as a sole conditioning agent in a Phase 1 dose-escalation trial to achieve donor stem cell engraftment in patients undergoing hematopoietic cell transplant for SCID, which is curable only by this type of treatment. For more information about the design of the clinical trial, visit www.clinicaltrials.gov
Clinical development of JSP191 will be expanded to also study patients with AML or MDS who are receiving hematopoietic cell transplant.
Qiming Venture Partners USA
Surveyor Capital (a Citadel company)
Roche Venture Fund
Alexandria Venture Investments LLC
Bill Lis, Executive Chairman and Interim CEO
William Lis has 28 years of biopharmaceutical experience. He is the Executive Chairman, and interim CEO of Jasper Therapeutics, Inc where he led the company’s 2019 Series A financing. Previously, Mr. Lis served as Chief Executive Officer and a Director of Portola Pharmaceuticals, Inc. from 2009 until 2018 after serving as Chief Operating Officer. Under his leadership, Portola successfully grew from a discovery-stage company to a fully integrated R&D and commercial organization, and independently discovered and developed Andexxa® and Bevyxxa® through commercial launch, and advanced cerdulatinib into clinical development. He led corporate partnerships and private and public financings including an initial public offering in 2013. The company grew into a multi-billion valuation company during his tenure. Mr. Lis held executive positions at Scios, Inc. (a Johnson & Johnson company) where he last served as Sr. Vice President of Business Development and New Product Development, having led efforts for the in-licensing, development and pre-commercial launch for Xarelto®; He also held positions of increasing responsibility at Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) and Rhone Poulenc Rorer in sales, marketing, medical affairs and business development. he was involved in the U.S. commercial launch of several products, including Integrilin®, Lovenox® and Rilutek®. Mr. Lis served as a member of the Bio Board of Directors for Emerging Companies and is currently an independent Director of Eidos Therapeutics, Inc. and Zai Laboratories, Inc. Mr. Lis holds a B.S. from the University of Maryland.
Judith Shizuru M.D., Ph.D., Co-Founder and Member Board of Directors
Dr. Shizuru is a Professor of Medicine (Blood and Marrow Transplantation) and Pediatrics (Stem Cell Transplantation) at Stanford. Dr. Shizuru is a member of the Stanford Blood and Marrow Transplantation (BMT) faculty, the Stanford Immunology Program and the Institute of Stem Cell Biology and Regenerative Medicine. She has attended on the BMT clinical service since 1997, and oversees a research laboratory focused on understanding the cellular and molecular basis of resistance to engraftment of transplanted allogeneic bone marrow (BM) cells and to understand the way in which BM grafts modify immune responses.
Jeet Mahal, Chief Financial and Business Officer
· Mr. Mahal joined Jasper from Portola, where he worked for 11 years and held a number of positions of increasing leadership, including Vice President of Business Development and Vice President, Strategic Marketing. He led the successful execution of multiple business development partnerships for Andexxa, Bevyxxa and cerdulatinib and played a key role in the company’s equity financings including the initial public offering and multiple royalty transactions. Earlier in his career, he was Director, Business and New Product Development at Johnson & Johnson on the Xarelto development and strategic marketing team. He started his career in the drug development laboratories at COR Therapeutics.
Susan Prohaska Ph.D., Co-Founder and Vice President Operations and Program Management
· Dr. Prohaska is a Stanford University-trained scientist in immunology and stem cell biology with over 20 years of experience in preclinical and early clinical research in immunology, hematopoieis, oncology and leading monoclonal antibody (mAb) development from discovery through early clinical stage. As Program Officer and Associate Director for Translational Programs at the Stanford Institute of Stem Cell Biology and Regenerative Medicine, and Program Director for JSP191 / AMG191 development for the Division of Blood and Marrow transplant, she managed CMC, toxicology, regulatory, preclinical and clinical operations for anti-CD47 and JSP191 drug development programs at Stanford University. Prior to founding Jasper, she served as Associate Director for CMC overseeing clinical manufacturing of FSI-5F9 (now magrolimab) at Forty Seven Inc. Prior to the recruitment of Mr. Lis, Dr. Prohaska served as founding Chief Executive Officer of Jasper.
Wendy Pang M.D., Ph. D., Executive Director, Discovery Research and Early Clinical Development
Dr. Pang will be joining Jasper from Stanford University where she was an Instructor in the Division of Blood and Marrow Transplantation. A physician-scientist with more than 18 years of experience conducting translational research in hematology/oncology and hematopoietic stem cell biology and transplantation, she was the lead scientist in the preclinical drug development of an anti-CD117 antibody at Stanford. She was the lead author on the proof-of-concept studies showing that an anti-CD117 antibody therapy targets disease-initiating human hematopoietic (blood cell-forming) stem cells in myelodysplastic syndrome (MDS). She has authored numerous publications on the characterization of hematopoietic stem and progenitor cell behavior in hematopoietic malignancies, including MDS and acute myeloid leukemia (AML), and in hematopoietic stem cell transplantation.
– –Funds will be used to advance JSP191, the first clinical-stage antibody designed for use as a single and combination conditioning agent in patients undergoing curative allogeneic hematopoietic cell transplant and autologous gene therapy–
–Jasper is pursuing new leads to expand its pipeline to include additional treatments for patients undergoing hematopoietic cell transplant or autologous gene therapy–
Palo Alto, Calif., January 9, 2020 – Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced the expansion of its Series A financing with an additional investment of $14.1 million led by Roche Venture Fund and with participation from other investors, bringing the total company financing to more than $50 million to date. The initial Series A round was led by Abingworth LLP and Qiming Venture Partners USA, with further investment from Surveyor Capital (a Citadel company) and participation from Alexandria Venture Investments, LLC.
– Initial data from Phase 1 clinical trial of JSP191, a humanized antibody targeting CD117, to be presented today at 3:00 p.m. ET in oral session at ASH 2019
– Company advancing clinical development of first-in-class antibody-based conditioning agent for patients undergoing potentially curative hematopoietic cell transplant
Orlando, Fl., December 9, 2019 – Jasper Therapeutics, Inc., a new biotechnology company focused on enabling safer conditioning and therapeutic agents that expand the application of curative hematopoietic stem cell transplants and gene therapies, today announced that initial results from an ongoing Phase 1 dose-escalation study of its lead product candidate, JSP191 (formerly AMG191), will be presented today in an oral session at the American Society of Hematology (ASH) Annual Meeting & Exposition.
– Initial results from company’s lead Phase 1 product, JSP191, targeting CD117, the first clinical-stage antibody-based conditioning agent in HCT, accepted as an oral presentation at upcoming American Society of Hematology (ASH) Annual Meeting –
- Jasper to focus on leveraging new advances in stem cell biology and translational science that will expand curative hematopoietic cell transplant (HCT) therapies for rare genetic disorders, autoimmune diseases and hematologic cancers –
-- Lead program advanced in collaboration with California Institute for Regenerative Medicine (CIRM), which is providing $23 million in grant support; Stanford University, which provided translational science and materials and Amgen, which discovered JSP191 (formerly AMG191) and licensed worldwide rights to Jasper –
Palo Alto, Calif., December 6, 2019 – Jasper Therapeutics, Inc., a new biotechnology company focused on enabling safer conditioning and therapeutic agents that expand the application of curative hematopoietic stem cell transplants and gene therapies, today announced the launch of the company with a $35 million total Series A financing. Abingworth LLP and Qiming Venture Partners USA served as lead investors, with further investment from Surveyor Capital (a Citadel company) and participation from Alexandria Venture Investments LLC. The proceeds will be used to advance the clinical development of the company’s lead product candidate, JSP191, which is designed to replace or reduce the toxicity of chemotherapy and radiation therapy as a conditioning regimen to prepare patients for hematopoietic cell transplant.